The biological rationale for synergy between IL-4 pathway inhibition and BV is supported by multiple mechanistic pathways: IL-4’s immunosuppressive remodeling of the tumor microenvironment, its modulation of CD30 expression, and its upregulation of anti-apoptotic signals all potentially intersect with BV’s mode of action. The gene discussed is IL4; the disease is neoplasm.